AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03475810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 1-2 mg midazolam will be administered before spinal punction performed.
Study NCT05217303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: HL-085 capsule administered orally twice daily (BID) in a 21-day treatment cycle
Study NCT03716050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 2,4,6, and 8 will include Nitroglycerin cream.
Study NCT03716050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy/ Wound VAC
Description: Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 3,4,7,and 8 will receive iVAC therapy.
Study NCT03716050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescent Angiography with indocyanine-green (not to exceed 5mg/kg)
Description: Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 5,6,7,and 8 will receive angiography.
Study NCT03716050 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 1 will include no treatment.
Study NCT03836807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKITASK®
Description: A single oral dose of OKITASK® 40 mg was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained KLS 40 mg (equivalent to 25 mg of ketoprofen). The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.
Study NCT03836807 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral dose of matching Placebo was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained Placebo. The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.
Study NCT01367964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenocorticotropin hormone
Description: ACTH 16 units intramuscular injection once daily for 2 weeks
Study NCT02663284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Description: Ropivacaine is used to performed the perineural block
Study NCT01348386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxide Potassium
Description: Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.
Study NCT01348386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04048980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARExDEM
Description: CARExDEM is an educational program addressed to nurses working in traumatology units and looking after patients with dementia. This intervention pretends to provide strategies to nurses for cognitive impairment management in acute hospital settings, to raise awareness about personalized care in dementia and to improve continuity of care in acute situations in PwD. Training sessions will be held to inform and train nurses about care of PwD and their caregivers by the research team in each hospital.
Study NCT01984944 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Autistic functional exploration
Description: * 50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~* 25 childs with urinary sample, Circadian rhythms assessed with actometer
Study NCT01984944 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control functional exploration
Description: * 50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~* 25 childs with urinary sample, Circadian rhythms assessed with actometer
Study NCT01442116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stress echocardiography
Description: safety and efficacy of stress echocardiography
Study NCT01255852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Patients in atorvastatin group will received 80 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
Study NCT03531788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armon Ayura (Kinova)
Description: Actively assisted mechanical arm support (electric powered to balance arm)
Study NCT03531788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JAECO Wrex
Description: Passive mechanical arm support (elastic bands to balance arm)
Study NCT00529451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren
Study NCT00529451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: comparator
Study NCT03732651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alteration of PaCO2 level
Description: step changes between 30, 40 and 50 mmHg
Study NCT02030405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given orally (PO)
Study NCT02486809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Participants will receive a single SC dose of lebrikizumab, delivered via needle and syringe or PFS-NSD.
Study NCT03645265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory
Description: Use of auditory cues to improve speech production
Study NCT03645265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gestures
Description: Use of gestures to improve speech production
Study NCT04650724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T cell infusion agent targeting BCMA chimeric antigen receptor
Description: Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
Study NCT02941926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib was centrally supplied to the investigators and administered orally once a day on days 1-21 of each 28 day cycle at a starting dose of 600 mg daily
Study NCT02941926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole was procured locally and administered orally once a day on a continuous daily schedule at a dose of 2.5 mg
Study NCT02941926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin was procured locally and administered in men and premenopausal women as an injectable subcutaneous implant administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 3.6 mg (cycle = 28 days)
Study NCT02941926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Leuprolide was procured locally and administered in men and premenopausal women as an injectable intramuscular depot administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 7.5 mg (cycle= 28 days)
Study NCT03661125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saracatinib
Description: AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.
Study NCT03661125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37. Two tablets to be taken every morning for 14 days.
Study NCT02693769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate/formoterol fumarate breath actuated inhaler
Study NCT02693769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/formoterol fumarate breath actuated inhaler
Study NCT02693769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol maleate / glycopyrronium bromide capsules
Study NCT02693769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate / glycopyrronium bromide capsules
Study NCT01318720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Thrust manipulation is a type of manual therapy that clinicians apply using a high-velocity, low-amplitude thrust directed at a joint(s)
Study NCT02376608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronova Pure 150:500 EE EU
Description: Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
Study NCT02376608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronovum PRF-037
Description: Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
Study NCT03666663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Nasal application using the Sphenocath device- cleared by FDA
Study NCT03666663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Saline using the Sphenocath device- cleared by FDA
Study NCT02376608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronovum PRF-041
Description: Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
Study NCT02376608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eskimo-3
Description: Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
Study NCT03769064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
Study NCT03769064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate 60 mg
Description: Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
Study NCT03769064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Phase Sequence 4213
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
Study NCT03769064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Phase Sequence 2134
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
Study NCT03769064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Phase Sequence 1342
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
Study NCT03769064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Phase Sequence 3421
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
Study NCT01668719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Given SC or IV
Study NCT01668719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC or IV
Study NCT01668719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT01668719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT01668719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV
Study NCT01668719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01668719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01668719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO
Study NCT01668719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT00684229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia and analgesia
Description: Post-operative analgesia will be epidural bupivacaine and fentanyl as well as intravenous morphine.
Study NCT04255238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin 50mg
Description: The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
Study NCT04255238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemigliptin 50mg
Description: The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
Study NCT04255238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
Study NCT04255238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
Study NCT03517878 — intervention group
Intervention type: BEHAVIORAL
Intervention: Comprehensive CHW Program
Description: The comprehensive CHW Cohort will receive home visits from CHWs recruited, trained, and supervised by the Philani organization. Philani has a 30-year history of non-stigmatizing home-based support for women and children in Cape Town. The organization has been operating their comprehensive CHW program in the rural Eastern Cape since 2010; however, in the research areas, CHWs have only been active for one year prior to initiation of the study. Philani recruits CHWs that are positive peer deviants to serve as role models in the community. The CHWs then receive training, materials, and skills to address major community health challenges of HIV, TB, malnutrition, alcohol use, and depression. The CHWs also receive ongoing monitoring and supervision as well as support for difficult cases.
Study NCT01895413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Single intra-articular injection of autologous bone marrow-derived mesenchymal stem cells by arthroscopy
Study NCT03527108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of nivolumab will be fixed at 240 mg. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
Study NCT03527108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of ramucirumab will depend upon the patient weight as noted below. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
Study NCT03008434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Yoga Group: designed for chronic TBI was provided two times a week for 8 weeks.
Study NCT00684229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia followed by opioid analgesia
Description: sevoflurane general anesthesia and postoperative opioid analgesia
Study NCT04272541 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation program
Description: Intervention program consisted of psychopharmacology + psychoeducation. This will be executed during 3 months, distribuited in several sessions.
Study NCT04272541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psychopharmacology intervention
Description: Intervention program consisted of psychopharmacology. This will be executed during 3 months.
Study NCT03882242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitation of a school-based program
Description: Participants deliver the prevention program (described in previous research) to school-children.
Study NCT03702803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galphimia glauca standardized extract
Description: Each patient will be administered with a capsule once a day (in the morning), for 10 weeks. A capsule contains the standardized extract of Galphimia glauca corresponding to 0.374 mg of Galphimine-B
Study NCT03702803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam 1mg
Description: Each patient will be administered once a day (in the morning) for 10 weeks. A capsule contains 1 mg Alprazolam
Study NCT04213014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guys/Girls Opt for Activities for Life (GOAL)
Description: The 4 month (16-wk) GOAL intervention has 3 components: (1) After-school GOAL Club: 26 events (2 days/week; 120 min/event/day; 13 weeks due to no club during 3 school break weeks) for boys and girls to engage in physical activity and healthy eating and cooking activities; (2) Three parent-adolescent meetings (1st meeting at each school for parents and adolescents \[Zoom option if needed\]; 2nd and 3rd meetings delivered virtually and asynchronously for parents): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality each week.
Study NCT01499472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shock wave therapy
Description: shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
Study NCT01499472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dermagold shockwave
Description: shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
Study NCT01499472 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard of care
Description: regular care including debridement and bandaging.
Study NCT01846325 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Study NCT01846325 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin E
Study NCT01846325 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Study NCT01846325 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Study NCT01846325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT01846325 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00387764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: 800 mg daily dosing continously until progression
Study NCT01184053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.